PHA-793887 hydrochloride

PHA-793887 hydrochloride 是一种 CDK 抑制剂,对 Cdk2(IC50 8 nM)、Cdk1(IC50 60 nM)、Cdk4(IC50 62 nM)和 Cdk9(IC50 138 nM)具有抑制作用,同时可抑制纯化的 GSK3β(IC50 79 nM),并能降低核仁磷酸蛋白/cdc6 的磷酸化水平、诱导 G1/G2/M 期阻滞、通过激活 Caspase-3 触发细胞凋亡(Apoptosis),对白血病具有抗癌活性,可用于急性白血病、慢性髓系白血病以及晚期/转移性实体瘤的相关研究。
产品编号: MS-M73348 CAS No.: 718630-60-5 分子式: C19H32ClN5O2 分子量: 397.94
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PHA-793887 hydrochloride 是一种 CDK 抑制剂,对 Cdk2(IC50 8 nM)、Cdk1(IC50 60 nM)、Cdk4(IC50 62 nM)和 Cdk9(IC50 138 nM)具有抑制作用,同时可抑制纯化的 GSK3β(IC50 79 nM),并能降低核仁磷酸蛋白/cdc6 的磷酸化水平、诱导 G1/G2/M 期阻滞、通过激活 Caspase-3 触发细胞凋亡(Apoptosis),对白血病具有抗癌活性,可用于急性白血病、慢性髓系白血病以及晚期/转移性实体瘤的相关研究。

生物实验数据

生物活性 PHA-793887 hydrochloride is a CDK inhibitor (Cdk2 (IC50 8 nM), Cdk1 (IC50 60 nM), Cdk4 (IC50 62 nM), Cdk9 (IC50 138 nM)) that also inhibits purified GSK3β (IC50 79 nM), reduces nucleophosmin/cdc6 phosphorylation, induces G1/G2/M phase arrest, triggers apoptosis via Caspase-3 activation, exhibits anticancer activity against leukemia, and can be used for research on acute leukemia, chronic myeloid leukemia, and advanced/metastatic solid tumors.
IC50 & Target CDK2:8 nM
体外研究
(In Vitro)

PHA-793887 hydrochloride 可强效抑制多种细胞周期蛋白依赖性激酶,其 IC50 值介于 5 至 140 nM 之间,且对包括 c-abl、c-kit、lck 和 TRKA 在内的非 cdk 激酶无活性。
PHA-793887 (0.01-10 μM; 48 h) hydrochloride 对一组白血病细胞系具有细胞毒性,其 IC50 值为 0.04 μM 至 >10 μM;对未受刺激的正常 PBMC 及 CD34+ 细胞无细胞毒性;且分别以 0.75 μM 和 1.85 μM 的 IC50 值抑制经丝裂原或生长因子刺激的正常造血细胞增殖。
PHA-793887 (0.04-5 μM; 24-48 h) hydrochloride 在敏感白血病细胞系 (697、KCL22、TOM1) 中,于 0.04~1 μM 浓度下诱导 G1 期细胞周期阻滞,在 5 μM 浓度下诱导细胞凋亡,但对耐试剂 KG1 细胞无作用;它在 5 μM 浓度下可激活 KCL22 细胞中的 caspase-3。
PHA-793887 hydrochloride 可强效抑制多种 CDK,包括 CDK2/细胞周期蛋白 A (IC50 = 0.008 μM),且在一组非 CDK 激酶中对 GSK3β 表现出选择性活性。
PHA-793887 hydrochloride 可抑制多种癌细胞系的增殖,其中对结肠癌细胞系 HCT-116 的抑制活性最强 (IC50 = 0.163 μM),对胰腺癌细胞系 BX-PC3 的抑制活性最弱 (IC50 = 3.444 μM)。
PHA-793887 (1-3 μM; 24 h) hydrochloride 可干扰 A2780 细胞的细胞周期进程并抑制其 DNA 合成,在 1 μM 时诱导 G1 期阻滞,在 3 μM 时诱导 G2/M 期阻滞并伴随细胞凋亡。
PHA-793887 hydrochloride 可在无细胞生化实验中强效抑制纯化的 Cdk2 (IC50 8 nM)、Cdk1 (IC50 60 nM)、Cdk4 (IC50 62 nM)、Cdk9 (IC50 138 nM) 及 GSK3β (IC50 79 nM),而对其他 35 种受试激酶无抑制作用。

Cell Viability Assay

Cell Line: 13 leukemic cell lines (K562, KCL22, KU812, TOM1, SUP-B15, REH, 697, RS4;11, HL60, KG1, RPMI8226, ALL-2, AML-PS), normal unstimulated peripheral blood mononuclear cells (PBMC), phytohemagglutinin-stimulated PBMC, normal unstimulated CD34+ hematopoietic stem cells, growth factor cocktail-stimulated CD34+ hematopoietic stem cells
Concentration: 0.01-10 μM
Incubation Time: 48 h
Result: Showed variable cytotoxicity across leukemic cell lines, with IC50 values ranging from 0.04 μM (most sensitive lines: TOM1, 697, RS4;11, HL60) to >10 μM (least sensitive lines: SUP-B15, KG1).
Primary leukemic cells ALL-2 and AML-PS had IC50 values of 3.4 μM and 6.2 μM, respectively.
Was not cytotoxic to unstimulated normal PBMC or CD34+ cells (IC50 >10 μM), but inhibited proliferation of stimulated PBMC (IC50 0.75 μM) and stimulated CD34+ cells (IC50 1.85 μM).

Cell Cycle Analysis

Cell Line: 697, KCL22, TOM1, and KG1 leukemic cell lines
Concentration: 0.04-5 μM
Incubation Time: 48 h (cell cycle analysis); 24 h (apoptosis analysis)
Result: Induced G1 phase arrest (14-40% increase compared to control) and reduced S-phase cell counts at doses of 0.04 to 1 μM in sensitive cell lines (697, KCL22, TOM1).
Induced a G2/M phase block (34% increase) in TOM1 cells at 1 μM.
Induced apoptosis (15-35% sub-G1 population) in sensitive cell lines at 5 μM.
Showed no significant cell cycle arrest or apoptosis in resistant KG1 cells at any dose.
Induced caspase-3 activation (43% positive cells, a 26% increase compared to control) in KCL22 cells at 5 μM, while 0.2 μM had no effect.

Cell Cycle Analysis

Cell Line: human ovarian carcinoma A2780 cells
Concentration: 1-3 μM
Incubation Time: 24 h
Result: Caused a 25% increase in G0/G1 population, 76% decrease in S phase population, 62% increase in G2/M population, and 85% reduction in BrdU incorporation relative to control at 1 μM.
Caused an 11% decrease in G0/G1 population, 48% decrease in S phase population, 263% increase in G2/M population, 100% reduction in BrdU incorporation, and an increase in sub-G1 cells (from 2.6% to 26.2%) indicative of apoptosis at 3 μM.
体内研究
(In Vivo)

PHA-793887 (20 mg/kg;静脉注射;每日 1 次;连续 10 天) hydrochloride 可诱导 SCID 小鼠的 HL60 皮下 AML 异种移植瘤消退,并产生 23.3 天的生长延迟。
PHA-793887 (20 mg/kg;静脉注射;每日 1 次;两个 5 天周期,周期间休息 3 天) hydrochloride 可显著抑制 K562 皮下 CML 异种移植物在 SCID 小鼠中的肿瘤生长,并导致其生长延迟 4.7 天。
PHA-793887 (20 mg/kg;静脉注射;每日 1 次;3 个 5 天周期,周期间隔 3 天休息期) hydrochloride 可使 SCID 小鼠预防性播散性 AML-PS 异种移植模型的中位生存期显著延长 7 天。
PHA-793887 (20 mg/kg;静脉注射;每日 1 次;3 个 5 天周期,周期间休息 3 天) hydrochloride 在 SCID 小鼠的预防性播散性 ALL-2 异种移植模型中可显著将中位生存期延长 22.5 天。
PHA-793887 (10-30 mg/kg;静脉注射;每日一次;连续 10 天) hydrochloride 在以 30 mg/kg 剂量每日静脉注射、连续给 10 天时,对 A2780 卵巢癌异种移植物展现出 76% 的肿瘤生长抑制作用,且可通过肿瘤细胞增殖能力下降及 pRb 磷酸化水平降低证实其体内靶点结合活性。
PHA-793887 (10-20 mg/kg;静脉注射;每日一次;连续 10 天) hydrochloride 在以 20 mg/kg 剂量静脉注射、每日一次、连续给 10 天时,对 HCT-116 结肠癌异种移植物表现出 81% 的肿瘤生长抑制作用,且耐受性良好。
PHA-793887 (20 mg/kg;静脉注射;每日一次;连续 10 天) hydrochloride 在以 20 mg/kg 静脉注射、每日一次、连续 10 天的方式时,对 BX-PC3 胰腺癌异种移植物表现出 84% 的肿瘤生长抑制作用,且耐受性良好。
PHA-793887 (15-30 mg/kg;静脉注射;每日;2-10 天) hydrochloride 在 CD-1 裸鼠的 A2780 卵巢癌异种移植物中可诱导剂量依赖性的肿瘤生长抑制 (15 mg/kg 时抑制率为 50%,30 mg/kg 时为 75%),并下调 E2F 依赖性基因特征。

Animal Model: SCID mice (unspecified gender, age not specified)
Dosage: 20 mg/kg
Administration: i.v.; once daily; 10 consecutive days
Result: Induced tumor regression.
Achieved a tumor growth delay of 23.3 days.
Left all treated mice tumor-free one week after treatment ended.
Caused no body weight loss or toxic effects.
Animal Model: SCID mice (unspecified gender, age not specified)
Dosage: 20 mg/kg
Administration: i.v.; once daily; two 5-day cycles with 3-day rest between cycles
Result: Significantly reduced tumor growth from day 14 compared to vehicle controls (p < 0.01).
Achieved a tumor growth delay of 4.7 days.
Caused no body weight loss or toxic effects.
Animal Model: SCID mice (5-week-old, unspecified gender)
Dosage: 20 mg/kg
Administration: i.v.; once daily; three 5-day cycles with 3-day rests between cycles
Result: Significantly increased median survival time by 7 days compared to vehicle controls (p < 0.0001).
Animal Model: SCID mice (5-week-old, unspecified gender)
Dosage: 20 mg/kg
Administration: i.v.; once daily; three 5-day cycles with 3-day rests between cycles
Result: Significantly increased median survival time by 22.5 days compared to vehicle controls (p < 0.0001).\nSignificantly increased median survival time by 22.5 days compared to vehicle controls (p < 0.0001).
Reduced tumor infiltration from 22.5% to 1.6% in peripheral blood after two treatment cycles.
Reduced tumor infiltration from 97.7% to 24.8% in bone marrow after two treatment cycles.
Reduced tumor infiltration from 91.6% to 44.7% in spleen after two treatment cycles.
Caused no body weight loss or toxic effects.
Animal Model: Nu/Nu (male)
Dosage: 10 mg/kg; 20 mg/kg; 30 mg/kg
Administration: i.v.; daily; 10 days
Result: Caused dose-dependent inhibition of A2780 tumor growth, reaching 76% tumor growth inhibition at the 30 mg/kg dose at the end of treatment.
Showed marginal body weight reduction (<10% vs control mice) and no toxic effects observed at gross autopsy.
Reduced tumor BrdU incorporation (p = 0.0022) and phosphorylated retinoblastoma protein (pRb) levels (p = 0.005) in mice treated with 30 mg/kg for 5 days compared to vehicle controls.
Animal Model: Nu/Nu (male)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.v.; daily; 10 days
Result: Caused dose-dependent inhibition of HCT-116 tumor growth, reaching 81% tumor growth inhibition at the 20 mg/kg dose at the end of treatment.
Showed marginal body weight reduction (<10% vs control mice) and no toxic effects observed at gross autopsy.
Animal Model: Nu/Nu (male)
Dosage: 20 mg/kg
Administration: i.v.; daily; 10 days
Result: Caused 84% tumor growth inhibition in BX-PC3 xenografts at the end of treatment.
Showed marginal body weight reduction (<10% vs control mice) and no toxic effects observed at gross autopsy.

化学信息

分子量 397.94
分子式 C19H32ClN5O2
CAS No. 718630-60-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础